Login to Your Account

Clinic Roundup

Tuesday, February 21, 2012

• BioMarin Pharmaceutical Inc., of Novato, Calif., said it started a Phase I study in healthy volunteers for BMN-111, an analogue of C-type natriuretic peptide in development for achondroplasia. The trial is a two-part study designed to test single and multiple subcutaneous doses of the drug in up to 74 subjects. Data are expected in the third quarter of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription